OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with HPV+ oropharyngeal squamous cell carcinoma were assigned to dose and volume de-escalated radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy in an effort to limit treatment-related toxicity while preserving efficacy. PATIENTS AND METHODS: Patients were classified as low-risk (≤T3, ≤N2B, ≤10 pack-year history) or high-risk (T4 or ≥N2C or >10 PYH). After three cycles of carboplatin/nab-paclitaxel, response was assessed using Response Evaluation Criteria in Solid Tumors 1.1. Low-risk patients with ≥50% response received 50 Gray (Gy) RT (RT50) while low-risk patients with 30%-50% response or high-risk patients with ≥50% response received 45 Gy CRT (CRT45). Patients with lesser response received standard-of-care 75 Gy CRT (CRT75). RT/CRT was limited to the first echelon of uninvolved nodes. The primary end point was 2-year progression-free survival compared with a historic control of 85%. Secondary end points included overall survival and toxicity. RESULTS: Sixty-two patients (28 low risk/34 high risk) were enrolled. Of low-risk patients, 71% received RT50 while 21% received CRT45. Of high-risk patients, 71% received CRT45. With a median follow-up of 29 months, 2-year PFS and OS were 95% and 100% for low-risk patients and 94% and 97% for high-risk patients, respectively. The overall 2-year PFS was 94.5% and within the 11% noninferiority margin for the historic control. Grade 3+ mucositis occurred in 30%, 63%, and 91% of the RT50, CRT45, and CRT75 groups, respectively (P = 0.004). Rates of any PEG-tube use were 0%, 31%, and 82% for RT50, CRT45, and CRT75 groups, respectively (P < 0.0001). CONCLUSIONS: Induction chemotherapy with response and risk-stratified dose and volume de-escalated RT/CRT for HPV+ OPSCC is associated with favorable oncologic outcomes and reduced acute and chronic toxicity. Further evaluation of induction-based de-escalation in large multicenter studies is justified. CLINICAL TRIAL REGISTRATION: Clinical trials.gov identifier: NCT02258659.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“1 response assessment including percent change in the largest diameter of primary/ nodal tumor lesions [8].”
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566 · cited 3×
“Patients were stratified into low-risk [T1-3, N0-2B unless bulky N2B conglomerate ( 6cm equivalent), and 10 pack-year history (PYH)] and high-risk (T4, N2C-3, bulky N2B disease, or >10 PYH) groups [1, 5, 6].”
(1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242402 · Cited by 2,733
Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., Westra, W. H., Gilbert, J., Bauman, J. E., Wagner, L. I., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3300 · Cited by 504 · cited 7×
“Specifically, induction chemotherapy has played an important role in organ preservation for laryngeal cancer [4], and its use in de-escalation protocols has been associated with favorable outcomes for HPV-unselected head and neck carcinoma [5] and for HPVþ OPSCC as reported in E1308 [6] and by Chen et al.”
InfluentialSelf-citationLate dysphagia after radiotherapy‐based treatment of head and neck cancer
Hutcheson, K. A., Lewin, J. S., Barringer, D. A., Lisec, A., Gunn, G. B., Moore, M. W. S., & Holsinger, F. C. (2012) · Cancer · doi:10.1002/cncr.27631 · Cited by 383
Chen, A. M., Felix, C., Wang, P.-C., Hsu, S., Basehart, V., Garst, J., Beron, P., Wong, D., Rosove, M. H., Rao, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30246-2 · Cited by 326 · cited 4×
“” Given possible implications for de-escalation suitability, using induction response to safely select for de-escalation candidates is an attractive approach [6, 7].”
InfluentialVokes, E. E., Stenson, K., Rosen, F. R., Kies, M. S., Rademaker, A. W., Witt, M. E., Brockstein, B. E., List, M. A., Fung, B. B., Portugal, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.006 · Cited by 234 · cited 1×
“This induction regimen was chosen based on institutional reports of excellent response rates with carboplatin/paclitaxel [9, 10], and nab-paclitaxel’s favorable pharmacokinetics [11].”
Self-citationRandomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab -Paclitaxel
Gardner, E. R., Dahut, W. L., Scripture, C. D., Jones, J., Aragon-Ching, J. B., Desai, N., Hawkins, M. J., Sparreboom, A., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4592 · Cited by 226 · cited 1×
“This induction regimen was chosen based on institutional reports of excellent response rates with carboplatin/paclitaxel [9, 10], and nab-paclitaxel’s favorable pharmacokinetics [11].”
Garden, A. S., Harris, J., Vokes, E. E., Forastiere, A. A., Ridge, J. A., Jones, C., Horwitz, E. M., Glisson, B. S., Nabell, L., Cooper, J. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.012 · Cited by 186 · cited 1×
“Nevertheless, comparable prospective outcomes at standard CRT doses [13, 18] have been observed in two randomized phase II studies with this platform.”
Self-citationChera, B. S., Amdur, R. J., Tepper, J. E., Tan, X. M., Weiss, J. M., Grilley‐Olson, J. E., Hayes, D. N., Zanation, A. M., Hackman, T., Patel, S. N., et al. (2018) · Cancer · doi:10.1002/cncr.31338 · Cited by 146 · cited 3×
“[12] for patients with HPVþ OPSCC who received a higher de-escalated dose of 60 Gy CRT without induction chemotherapy.”
Influential
Cited by
Chow, L. Q. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1715715 · Cited by 2,075
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management
Lechner, M., Liu, J., Masterson, L., & Fenton, T. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00603-7 · Cited by 979
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Modern radiotherapy for head and neck cancer
Alterio, D., Marvaso, G., Ferrari, A., Volpe, S., Orecchia, R., & Jereczek-Fossa, B. A. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.07.002 · Cited by 295
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., et al. (2022) · Biomolecules · doi:10.3390/biom12060784 · Cited by 274
Metadata
- Authors
- Seiwert, T. Y., Foster, C. C., Blair, E. A., Karrison, T. G., Agrawal, N., Melotek, J. M., Portugal, L., Brisson, R. J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M. W., Villaflor, V. M., Ginat, D. T., Haraf, D. J., & Vokes, E. E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 30
- Issue
- 2
- Pages
- 297-302
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2902299732
- Cited by
- 237
- References
- 12
- FWCI
- 20.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.